



ACIP COVID-19 Vaccines Work Group

Dr. Matthew F. Daley, Work Group Chair

June 27, 2024

2023-2024 COVID-19 vaccine recommendations

- ACIP met September 12, 2023 and recommended 2023-2024 COVID-19 vaccines as authorized under EUA or approved by BLA in persons aged ≥ 6 months
 - Moderna COVID-19 vaccine in persons ≥ 6 months
 - Pfizer-BioNTech COVID-19 vaccine in persons ≥ 6 months
 - Novavax COVID-19 vaccine in persons ≥ 12 years*
- Everyone aged 5 years and older should get 1 dose of a 2023-2024 COVID-19 vaccine to protect against serious illness from COVID-19
- Children aged 6 months–4 years need multiple doses of COVID-19 vaccines to be up to date, including at least 1 dose of 2023-2024 COVID-19 vaccine
- People who are moderately or severely immune compromised may receive additional doses of COVID-19 vaccines
- On February 28, 2024 ACIP recommended that adults ages 65 years and older receive one additional 2023-2024 COVID-19 vaccine dose

Abbreviations – EUA: Emergency Use Authorization, BLA: Biologics License Application

*People aged 12 years and older who have not previously received any COVID-19 vaccine doses and choose to get Novavax should get 2 doses of updated Novavax vaccine to be up to date.

February 2024 ACIP Meeting Review

- Reviewed evidence to inform recommendations for an additional dose of the 2023-2024 COVID-19 vaccine for adults ages 65 years and older, including:
 - COVID-19 hospitalizations
 - COVID-19 vaccine coverage
 - COVID-19 vaccine effectiveness
 - Economic analysis of additional COVID-19 vaccine doses
 - Evidence to Recommendations
- ACIP voted to recommend an additional dose of 2023-2024 COVID-19 vaccine in persons ≥ 65 years
- Discussed next steps for the COVID-19 vaccine program, including shifting to a vote at the June ACIP meeting for future vaccine updates

ACIP COVID-19 Work Group Meeting Review – Initial planning

- Framing of the policy question for the 2024-2025 vaccine
 - Started with considerations for universal v. risk-based recommendations
 - Reviewed international COVID-19 vaccination policies from countries with risk-based and age-based recommendations
 - Discussed complexity of a risk-based recommendation, including
 - Defining risk groups for severe outcomes
 - Whether to take into account high risk of exposure
 - Recommendations for persons not meeting risk criteria, including those not previously vaccinated
 - Discussed implementation challenges of non-universal policy options
 - Work Group consensus was to proceed with deliberations for a universal recommendation for everyone ages ≥ 6 months for 2024-2025 vaccine

ACIP COVID-19 Work Group Meeting Review

March – June 2024

- Framing of the policy question for the 2024-2025 vaccine
- Updated data on COVID-19 epidemiology, including risk factors for hospitalization due to COVID-19 and epidemiology of Multisystem Inflammatory Syndrome in Children (MIS-C) and Post-COVID Conditions
- Vaccine effectiveness of the 2023-2024 COVID-19 vaccine
- Review of COVID-19 vaccine safety including longer-term outcomes of myocarditis
- Economic analysis of COVID-19 vaccination
- COVID-19 vaccine program implementation considerations
- Evidence to Recommendations Framework

COVID-19 vaccine 2024-2025 Formula: VRBPAC Meeting

- June 5, 2024: FDA's Vaccines and Related Biological Products Advisory Committee (VRBPAC) met to discuss strain selection for 2024-2025 COVID-19 vaccines
 - Based on the totality of the evidence presented, FDA advised manufacturers to develop monovalent JN.1 lineage COVID-19 vaccines, with a preference for the KP.2 strain, if feasible
 - Anticipated 2024-2025 vaccine doses will be broadly available in the fall

Agenda: June 27, 2024

COVID-19-associated hospitalizations

Dr. Fiona Havers

COVID-19 vaccine effectiveness update

Dr. Ruth Link-Gelles

Vaccine safety update for 2023-2024 COVID-19 vaccine

Dr. Jonathan Duffy

Economic analysis of COVID-19 vaccination

Dr. Lisa Prosser

Evidence to recommendations

Dr. Lakshmi Panagiotakopoulos

COVID-19 vaccine implementation

Dr. Shannon Stokely

Vote: 2024-2025 COVID-19 vaccines in persons ages 6 months and older

Work Group members

ACIP members

- Matthew Daley (chair)
- Oliver Brooks
- Robert Schechter
- Keipp Talbot

Ex-officio/government members

- BARDA: Christine Oshansky
- CDC: Alan Lam
- FDA: Rachel Zhang, Adam Spanier
- IHS: Uzo Chukwuma
- NIH: Chris Roberts

CDC co-Leads

- Megan Wallace
- Lakshmi Panagiotakopoulos

Liaisons

- AAFP: Jonathan Temte
- AAP: Sean O’Leary
- ACOG: Naima Joseph (primary),
Laura Riley (alternate)
- ACP: Jason Goldman
- AGS: Ken Schmader
- AIM: Heather Roth
- AMA: Sandra Fryhofer
- ANA: Ruth Francis
- APhA: Richard Dang
- ASTHO: Marcus Plescia
- CSTE: Paul Cieslak, Christine Hahn
- IDSA: Jeff Duchin

Liaisons, cont’d

- NACCHO: Matt Zahn (primary),
Jeff Duchin (alternate)
- NACI: Eva Wong (primary),
Matthew Tunis (alternate)
- NFID: Robert Hopkins (primary),
Bill Schaffner (alternate)
- SHEA: Preeti Mehrotra (primary),
Marci Drees (alternate)

Consultants

- Beth Bell
- Ed Belongia
- Hank Bernstein
- Kathy Edwards
- Lisa Jackson
- Kathy Kinlaw
- Grace Lee
- Dayna Matthew
- Jennifer Nelson
- Stanley Perlman
- Peter Szilagyi

CDC participants

- Sarah Meyer
- Elisha Hall
- Danielle Moulia
- Monica Godfrey
- Hannah Rosenblum
- Katherine Fleming-Dutra
- Ruth Link-Gelles
- Lauren Roper
- Mary Chamberland
- Susan Goldstein
- Stephen Hadler
- JoEllen Wolicki
- Melinda Wharton
- Jessica MacNeil
- Latifa Boyce
- Amadea Britton
- Karen Broder
- Carolyn Bridges
- Allison Ciesla
- Nicole Dowling
- Daniel Drapeau
- Kristen Folsom
- Ashley Fowlkes
- Jarrett Gartin
- Julianne Gee
- Samuel Graitcer
- Elizabeth Greene
- Lisa Grohskopf
- Aron Hall
- Demorah Hayes
- Rita Helfand
- Michele Hlavsa
- Terri Hyde
- Jefferson Jones
- Andrew Kroger
- Josephine Mak
- Lauri Markowitz
- Michael McNeil
- Michael Melgar
- Noelle-Angelique Molinari
- Morgan Najdowski
- Kristen Nordlund
- Ismael Ortega-Sanchez
- Manisha Patel
- Pragna Patel
- Amanda Payne
- Georgina Peacock
- Jamison Pike
- Derrell Powers
- Sierra Scarbrough
- Jordan Singleton
- Laura Steinhardt
- John Su
- Natalie Thornburg
- Evelyn Twentyman
- David Wentworth
- Dennis Wang
- Raigan Wheeler
- Ryan Wiegand
- Trang Wisard
- Patricia Yu
- Yon Yu

For more information, contact CDC
1-800-CDC-INFO (232-4636)
TTY: 1-888-232-6348 [cdc.gov](https://www.cdc.gov)

The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the U.S. Centers for Disease Control and Prevention.

